Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dragon Sail Pharmaceutical Co., Ltd. (also known as Baifan Biotech) is a high-tech contract development and manufacturing organization (CDMO) specializing in antibody drugs. Founded in 2016 as a subsidiary of Guilin Sanjin Pharmaceutical, the company operates a state-of-the-art, 12,000L capacity manufacturing facility in the Shanghai Lin-gang Special Area. It features the proprietary NONCROS platform, which is China's first cross-contamination-free antibody production facility designed to meet US, EU, and Chinese cGMP standards. Dragon Sail Pharmaceutical provides end-to-end services from sequence to IND, clinical sample production, BLA, and commercial manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, and antibody-drug conjugates (ADCs).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 白帆生物科技.